RhumbLine Advisers
SANA icon

RhumbLine Advisers’s Sana Biotechnology SANA Stock Holding History

RhumbLine Advisers’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$572K Buy
198,696
+9,284
+5% +$36.6K ﹤0.01% 2526
2025
Q4 		$771K Sell
189,412
-6,294
-3% -$28.2K ﹤0.01% 2374
2025
Q3 		$695K Sell
195,706
-7,577
-4% -$27.4K ﹤0.01% 2469
2025
Q2 		$555K Buy
203,283
+21,149
+12% +$43.6K ﹤0.01% 2624
2025
Q1 		$306K Buy
182,134
+9,359
+5% +$26.2K ﹤0.01% 2877
2024
Q4 		$282K Buy
172,775
+987
+0.6% +$2.94K ﹤0.01% 3027
2024
Q3 		$715K Sell
171,788
-10,115
-6% -$53.1K ﹤0.01% 2465
2024
Q2 		$993K Buy
181,903
+25,056
+16% +$200K ﹤0.01% 2253
2024
Q1 		$1.57M Buy
156,847
+4,863
+3% +$36.4K ﹤0.01% 2028
2023
Q4 		$620K Buy
151,984
+1,866
+1% +$6.87K ﹤0.01% 2542
2023
Q3 		$581K Sell
150,118
-2,732
-2% -$14.7K ﹤0.01% 2522
2023
Q2 		$911K Buy
152,850
+10,258
+7% +$59.1K ﹤0.01% 2345
2023
Q1 		$466K Buy
142,592
+4,260
+3% +$17K ﹤0.01% 2471
2022
Q4 		$546K Buy
138,332
+770
+0.6% +$3.77K ﹤0.01% 2423
2022
Q3 		$825K Buy
137,562
+7,543
+6% +$54.4K ﹤0.01% 2247
2022
Q2 		$836K Buy
130,019
+39,323
+43% +$251K ﹤0.01% 2223
2022
Q1 		$749K Buy
90,696
+5,518
+6% +$44.6K ﹤0.01% 2251
2021
Q4 		$1.32M Buy
85,178
+1,529
+2% +$29.5K ﹤0.01% 2092
2021
Q3 		$1.88M Buy
83,649
+59,808
+251% +$1.26M ﹤0.01% 1939
2021
Q2 		$469K Buy
23,841
+2,860
+14% +$64.8K ﹤0.01% 2592
2021
Q1 		$702K Buy
+20,981
New +$683K ﹤0.01% 2344

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

RhumbLine Advisers's SANA Position: Q1 2026 in Review

RhumbLine Advisers increased its Sana Biotechnology (SANA) stake by 4.9% in Q1 2026, buying an estimated $36.6K and bringing the position to 198,696 shares worth $572K. The position accounts for ﹤0.01% of the portfolio, ranked #2526.

RhumbLine Advisers first reported a position in SANA in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.88M in Q3 2021. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • RhumbLine Advisers held 198,696 shares of Sana Biotechnology worth $572K as of Q1 2026.
  • RhumbLine Advisers bought 9,284 Sana Biotechnology shares in Q1 2026, an estimated $36.6K.
  • Sana Biotechnology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2526 holding.
  • RhumbLine Advisers first reported a position in Sana Biotechnology in Q1 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Sana Biotechnology position peaked at $1.88M in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.